Qualigen Therapeutics, Inc. announced publication of key data in the peer-reviewed journal Molecules. The publication explained that the Company's lead compound QN-302 had high anti-proliferative activity against pancreatic cancer cell lines, and anti-tumor activity in several in vivo models of the disease. The data also showed QN-302 causes downregulation of the expression of the S100P gene and the S100P protein in cells and in vivo.

S100P is identified in connection with several human cancers and has been well documented as a potential biomarker specifically for pancreatic cancer. Pancreatic cancer remains a lethal disease and the third most common cause of cancer deaths in the United States. In vitro and in vivo pre-clinical studies of QN-302 have shown that G4 stabilization may result in inhibition of target gene expression and cessation of cell growth in a variety of cancers, including pancreatic ductal adenocarcinoma (PDAC), which represents 98% of pancreatic cancers.